Teva Pharmaceutical Indus Analyst Ratings
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Piper Sandler Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $19
Teva Pharmaceutical Indus Analyst Ratings
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $17
Teva Pharmaceutical Indus Analyst Ratings
UBS Remains a Buy on Teva Pharmaceutical (TEVA)
Teva Pharmaceutical Indus Analyst Ratings
Barclays Remains a Buy on Teva Pharmaceutical (TEVA)
Jefferies Upgrades Teva Pharmaceutical Indus to Buy, Raises Price Target to $14
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating
Piper Sandler Upgrades Teva Pharmaceutical Indus to Neutral, Raises Price Target to $12
Teva Pharmaceutical Indus Analyst Ratings